$15,456 to Enroll 113 U.S Adults With Schizophrenia

In late 2018 Novartis Pharmaceuticals, together with Pear Therapeutics, announced a phase 2 clinical trial to investigate digital therapy for adults diagnosed with Schizophrenia. The study needed to enroll 113 Adults across 9 sites in California, Florida, Michigan and New Mexico. The study did not use Wayturn’s digital advertising services to enroll participants. However, this… Continue reading $15,456 to Enroll 113 U.S Adults With Schizophrenia